A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer.

Bral, Samuel; Van Parijs, Hilde; Soete, Guy; Linthout, Nadine; Van Moorter, Lutgard; Verellen, Dirk; Storme, Guy · Radiother Oncol · 2007

case_series · Level IV

Where this comes from

Abstract

We treated 36 cases of stage I/II non-small cell lung cancer in inoperable patients. Treatments were planned to a total isocenter dose of 60Gy (8x7.5Gy) based on a dynamic field shaping arc, employing one arc to span as much area as possible and if needed additional weighted segments. The 2 year infield progression free probability is 65%. Disease-specific survival is 75% at 2 years. No patients experienced grade 3-4 toxicity.

Medical subject headings